Lateral Flow Reader Quantifies Antibody Avidity for HIV Duration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for assessing HIV infection duration, such as the BED Assay, are less accurate in estimating duration compared to measuring antibody avidity, and existing lateral flow tests lack the capability to quantify antibody avidity and infection duration effectively.
Innovation Solution
A lateral flow test device with a porous matrix and a reader configured to measure signal pixels and intensities, generating a quantitative signal readout to assess average antibody avidity and estimate HIV infection duration, incorporating a recency line to differentiate recent from long-term infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a lateral flow test device is used for rapid testing, then the testing speed and ease of operation are improved, but the measurement precision and ability to quantify antibody avidity deteriorate
Solution Approach 1:
The lateral flow test device is enhanced to perform multiple functions: it not only detects the presence of anti-HIV antibodies but also quantifies antibody avidity through the recency line signal intensity measurement, and estimates infection duration. This multi-functionality allows a single rapid test device to provide comprehensive diagnostic information previously requiring multiple separate assays.
Solution Approach 2:
The patent replaces complex laboratory-based avidity assays with a simplified lateral flow format that uses optical signal intensity measurement. The reader device automatically captures and quantifies the recency line signal, substituting manual laboratory procedures with an automated optical measurement system that maintains measurement precision while improving ease of operation.
2Ease of operation
If existing lateral flow tests are used, then the ease of operation is improved, but the measurement precision and accuracy in estimating infection duration worsen
Solution Approach 1:
The recency line acts as an intermediary element that bridges the gap between simple presence/absence detection and quantitative avidity measurement. By measuring the signal intensity at this intermediate position, the device extracts quantitative information about antibody avidity and infection duration while maintaining the simplicity of the lateral flow format.
Solution Approach 2:
The patent changes the measurement parameter from binary (presence/absence of line) to continuous (signal intensity of recency line). This parameter change enables quantitative assessment of antibody avidity and estimation of infection duration, significantly improving measurement precision while keeping the test format simple and easy to operate.
3Measurement precision
If a recency line with limiting antigen concentration is added, then the ability to differentiate recent from long-term infections is improved, but the device complexity increases
Solution Approach 1:
Instead of adding more test lines in the traditional horizontal dimension, the patent utilizes the vertical dimension of signal intensity. The recency line's signal strength provides the additional information layer needed to differentiate infection recency, allowing the device to maintain a simple two-line structure while achieving enhanced diagnostic capability through quantitative signal measurement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a more accurate assessment of HIV infection duration by correlating antibody avidity with mean duration of recent infection, enhancing the ability to distinguish between recent and long-term infections and offering a flexible cutoff for incidence estimation.
Implementation Method 1
a porous matrix that comprises, from upstream to downstream, a sample application site configured to receive a sample liquid from a subject, and a first test location comprising an immobilized first binding reagent
Implementation Method 2
a first test location comprising an immobilized first binding reagent that specifically binds to an anti-viral antibody, e.g., anti-HIV antibody, in said sample liquid
Data Source
AI summary
The present disclosure relates to systems and methods for assessing viral, e.g., HIV, infection duration in a subject. More specifically, the present disclosure relates to for assessing viral, e.g., HIV, infection duration in a subject using, inter alia, a reader configured to measure both the number of signal pixels and the intensities of signal pixels to generate a quantitative signal readout that is used to assess average antibody avidity of an anti-viral antibody, e.g., an anti-HIV antibody, in a sample liquid and/or viral, e.g., HIV, infection duration in a subject.